Latest research report on “Rivaroxaban Market” now available at high quality database of ReportsnReports.com with market size, share, trends, competitive and statistical analysis. An exclusive data offered in this report is collected by research and industry experts team.
Get Free Sample Copy @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=5552228
Rivaroxaban is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceutica. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects last approximately 812 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.
This report contains market size and forecasts of Rivaroxaban in global, including the following market information:
Global Rivaroxaban Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Rivaroxaban Market Sales, 2017-2022, 2023-2028, (M Units)
Global top five Rivaroxaban companies in 2021 (%)
The global Rivaroxaban market was valued at 8226.5 million in 2021 and is projected to reach US$ 13960 million by 2028, at a CAGR of 7.8% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
2.5 mg Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Rivaroxaban include Bayer and J&J etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Rivaroxaban manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Rivaroxaban Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (M Units)
Global Rivaroxaban Market Segment Percentages, by Type, 2021 (%)
– 2.5 mg
– 10 mg
– 15 mg
– 20 mg
Global Rivaroxaban Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (M Units)
Global Rivaroxaban Market Segment Percentages, by Application, 2021 (%)
– Acute Coronary Syndrome (ACS)
– Venous Thromboembolism (VTE)
Global Rivaroxaban Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (M Units)
Global Rivaroxaban Market Segment Percentages, By Region and Country, 2021 (%)
– North America
– – US
– – Canada
– – Mexico
– – Germany
– – France
– – U.K.
– – Italy
– – Russia
– – Nordic Countries
– – Benelux
– – Rest of Europe
– – China
– – Japan
– – South Korea
– – Southeast Asia
– – India
– – Rest of Asia
– South America
– – Brazil
– – Argentina
– – Rest of South America
– Middle East & Africa
– – Turkey
– – Israel
– – Saudi Arabia
– – UAE
– – Rest of Middle East & Africa
The report also provides analysis of leading market participants including:
Key companies Rivaroxaban revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Rivaroxaban revenues share in global market, 2021 (%)
Key companies Rivaroxaban sales in global market, 2017-2022 (Estimated), (M Units)
Key companies Rivaroxaban sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
More information about Discount offers (25% or More) @ https://www.reportsnreports.com/contacts/discount.aspx?name=5552228
About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.
We provide 24/7 online and offline support to our customers.
E-mail: [email protected]
Phone: +1 888 391 5441